#USA #Cambridge #cancer therapy #ARTBIO #Alpha Radioligand

ARTBIO Secures $132 Million in Series B Financing

On July 29, 2025, ARTBIO, a clinical-stage company focused on developing alpha radioligand therapies (ARTs) for cancer treatment, announced the closing of a significant $132 million Series B financing round. This funding comes from a mix of new and existing investors, demonstrating strong confidence in ARTBIO's innovative approaches to cancer care.

The financing was co-led by Sofinnova Investments and B Capital, alongside contributions from familiar faces such as F-Prime, Omega Funds, and Third Rock Ventures. Notably, new entrants like Qatar Investment Authority and Alexandria Venture Investments have joined the fold, amplifying the potential of ARTBIO's initiatives.

ARTBIO's funding will primarily bolster the advancement of its lead asset, AB001, targeted at treating metastatic castration-resistant prostate cancer, as it moves into Phase II clinical trials. This crucial investment will also finance the development of additional undisclosed programs, further establishing ARTBIO's pipeline of effective therapies.

Dr. Emanuele Ostuni, CEO of ARTBIO, expressed gratitude for the support received from investors, stating, “This sizable investment will allow us to continue innovating therapies designed to combat various aggressive cancers with precision.” A key component of this development focuses on enhancing the supply chain to ensure that ARTBIO's therapies are manufactured and delivered effectively, matching their high efficacy.

To support its advanced pipeline, ARTBIO is also set to expand its manufacturing infrastructure, which is essential for supplying ongoing clinical trials and, eventually, commercializing their progressive therapies. The company recognizes that building a robust supply chain is crucial for the success of its product offerings.

Dr. Robert Mittendorff, a General Partner at B Capital, noted the transformative potential ARTBIO holds within cancer treatment paradigms. “ARTBIO's approach can significantly alter the standard of care for patients with cancer,” he remarked.

At the center of ARTBIO's success is its patented AlphaDirect™ isotope isolation technology. This innovative solution allows for the flexible production of clinical-grade lead-212 isotopes, providing daily therapeutic doses. ARTBIO’s strategically distributed manufacturing network mitigates supply chain risks, enhancing access to essential resources.

Dr. Maha Katabi, General Partner at Sofinnova Investments, praised ARTBIO's unique ART portfolio and integrated manufacturing approach. She emphasized, “Their proprietary generator technology truly revolutionizes how we navigate the complexities of radioisotope production.”

ARTBIO aims to reshape cancer care with its distinct method of selecting optimal alpha-precursor isotopes combined with tumor-specific targets, creating treatments with enhanced safety and effectiveness. Leveraging its innovative AlphaDirect™ technology and a legacy of pioneering work in radiation therapy from the University of Oslo and Norway's Radium Hospital, ARTBIO is set to redefine cancer treatment paradigms.

About ARTBIO

ARTBIO is at the forefront of clinical-stage radiopharmaceutical development, focused on creating a new class of alpha radioligand therapies that redefine treatment strategies for cancer patients. As ARTBIO progresses with its lead program, AB001, currently undergoing first-in-human trials for treating advanced prostate cancer, the company continues to advance multiple pipeline programs, equipped with state-of-the-art technology essential for reliable therapy production.

For more information, please visit www.artbio.com and follow their updates on LinkedIn.